These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25873167)

  • 61. Taspase 1: A protease with many biological surprises.
    Niizuma H; Cheng EH; Hsieh JJ
    Mol Cell Oncol; 2015; 2(4):e999513. PubMed ID: 27308523
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development of an orally bioavailable selective inhibitor of the menin-MLL.
    Zhong HJ; Wang W; Zhou W; Liang JX; Cheng YC; Ma DL; Leung CH
    Genes Dis; 2023 Sep; 10(5):1735-1738. PubMed ID: 37492738
    [No Abstract]   [Full Text] [Related]  

  • 63. Therapy: It's raining menin.
    Danovi S
    Nat Rev Cancer; 2015 May; 15(5):256-7. PubMed ID: 25877330
    [No Abstract]   [Full Text] [Related]  

  • 64. When one mutation is all it takes.
    Greaves M
    Cancer Cell; 2015 Apr; 27(4):433-4. PubMed ID: 25873168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
    Chen CW; Armstrong SA
    Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.
    He S; Malik B; Borkin D; Miao H; Shukla S; Kempinska K; Purohit T; Wang J; Chen L; Parkin B; Malek SN; Danet-Desnoyers G; Muntean AG; Cierpicki T; Grembecka J
    Leukemia; 2016 Feb; 30(2):508-13. PubMed ID: 26084867
    [No Abstract]   [Full Text] [Related]  

  • 67. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.
    Shih AH; Jiang Y; Meydan C; Shank K; Pandey S; Barreyro L; Antony-Debre I; Viale A; Socci N; Sun Y; Robertson A; Cavatore M; de Stanchina E; Hricik T; Rapaport F; Woods B; Wei C; Hatlen M; Baljevic M; Nimer SD; Tallman M; Paietta E; Cimmino L; Aifantis I; Steidl U; Mason C; Melnick A; Levine RL
    Cancer Cell; 2015 Apr; 27(4):502-15. PubMed ID: 25873173
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
    Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
    Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility.
    Senter T; Gogliotti RD; Han C; Locuson CW; Morrison R; Daniels JS; Cierpicki T; Grembecka J; Lindsley CW; Stauffer SR
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2720-5. PubMed ID: 25987377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
    Rao RC; Dou Y
    Nat Rev Cancer; 2015 Jun; 15(6):334-46. PubMed ID: 25998713
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epigenetic modifiers in normal and malignant hematopoiesis.
    Haladyna JN; Yamauchi T; Neff T; Bernt KM
    Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tumor suppressor Menin acts as a corepressor of LXRα to inhibit hepatic lipogenesis.
    Cheng P; Li G; Yang SS; Liu R; Jin G; Zhou XY; Hu XG
    FEBS Lett; 2015 Oct; 589(20 Pt B):3079-84. PubMed ID: 25962847
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting cell cycle regulators in hematologic malignancies.
    Aleem E; Arceci RJ
    Front Cell Dev Biol; 2015; 3():16. PubMed ID: 25914884
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
    Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
    Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.
    Kim E; Ilagan JO; Liang Y; Daubner GM; Lee SC; Ramakrishnan A; Li Y; Chung YR; Micol JB; Murphy ME; Cho H; Kim MK; Zebari AS; Aumann S; Park CY; Buonamici S; Smith PG; Deeg HJ; Lobry C; Aifantis I; Modis Y; Allain FH; Halene S; Bradley RK; Abdel-Wahab O
    Cancer Cell; 2015 May; 27(5):617-30. PubMed ID: 25965569
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells.
    Elsässer SJ; Noh KM; Diaz N; Allis CD; Banaszynski LA
    Nature; 2015 Jun; 522(7555):240-244. PubMed ID: 25938714
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
    Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
    Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Roles of mTORC1 in acute myeloid leukemia].
    Hoshii T; Hirao A
    Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.